ADMA Biologics (NASDAQ:ADMA) Upgraded at Canaccord Genuity Group

Canaccord Genuity Group upgraded shares of ADMA Biologics (NASDAQ:ADMA) to a strong-buy rating in a research report released on Monday morning,Zacks.com reports.

A number of other brokerages have also recently issued reports on ADMA. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Wall Street Zen cut shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Mizuho reduced their target price on shares of ADMA Biologics from $30.00 to $24.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. Zacks Research raised ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Three analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $25.67.

ADMA Biologics Trading Up 1.6%

ADMA stock opened at $10.95 on Monday. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. The company has a fifty day moving average price of $13.12 and a two-hundred day moving average price of $15.72. ADMA Biologics has a one year low of $7.21 and a one year high of $25.67. The stock has a market cap of $2.61 billion, a price-to-earnings ratio of 18.25 and a beta of 0.82.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 EPS for the quarter, hitting analysts’ consensus estimates of $0.20. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The firm had revenue of $139.16 million during the quarter, compared to analysts’ expectations of $139.80 million. During the same period in the previous year, the business posted $0.46 earnings per share. The company’s revenue for the quarter was up 18.4% compared to the same quarter last year. Equities analysts anticipate that ADMA Biologics will post 0.93 EPS for the current year.

Insider Activity

In other news, Director Steve Elms purchased 7,000 shares of ADMA Biologics stock in a transaction dated Thursday, March 5th. The shares were bought at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the acquisition, the director owned 2,038,730 shares in the company, valued at approximately $31,946,899.10. This trade represents a 0.34% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $15.63, for a total transaction of $157,800.48. Following the sale, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at $7,292,958. This represents a 2.12% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 3.50% of the company’s stock.

Hedge Funds Weigh In On ADMA Biologics

A number of institutional investors and hedge funds have recently modified their holdings of ADMA. Salomon & Ludwin LLC bought a new position in shares of ADMA Biologics in the 3rd quarter worth $25,000. Rothschild Investment LLC lifted its holdings in shares of ADMA Biologics by 373.8% in the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,495 shares in the last quarter. Summit Securities Group LLC bought a new position in shares of ADMA Biologics in the 4th quarter worth $29,000. Clearstead Advisors LLC lifted its holdings in shares of ADMA Biologics by 55.7% in the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 795 shares in the last quarter. Finally, iSAM Funds UK Ltd bought a new position in shares of ADMA Biologics in the 3rd quarter worth $34,000. 75.68% of the stock is currently owned by institutional investors.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.